LCM
SYRE icon

Laurion Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Laurion Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-63,026
Closed -$3.62M – 690
2022
Q1 		$3.62M Buy
63,026
+5,000
+9% +$420K 0.04% 176
2021
Q4 		$6.89M Buy
58,026
+33,760
+139% +$5.33M 0.07% 163
2021
Q3 		$4.82M Buy
+24,266
New +$4.24M 0.02% 347

Other funds holding SYRE

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Laurion Capital Management's SYRE Position: Q2 2022 in Review

Laurion Capital Management sold out of Spyre Therapeutics (SYRE) in Q2 2022, closing a stake of 63,026 shares — an estimated $3.62M sold.

Laurion Capital Management first reported a position in SYRE in Q3 2021 and held it in 3 quarters. The position peaked at $6.89M in Q4 2021. 66 funds tracked by Wall St. Rank hold SYRE as of Q2 2022.

  • Laurion Capital Management reported no remaining Spyre Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Laurion Capital Management sold 63,026 Spyre Therapeutics shares in Q2 2022, an estimated $3.62M.
  • Laurion Capital Management first reported a position in Spyre Therapeutics in Q3 2021 and held it in 3 quarters.
  • Laurion Capital Management's Spyre Therapeutics position peaked at $6.89M in Q4 2021.
  • 66 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2022.

Based on Laurion Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.